These Tiny “Power Plants” Living Inside You

Dear Tech Profits Reader,

Happy New Year, folks… I hope you enjoyed your holiday.

Looking into 2019 we have some very exciting opportunities, despite the overall bearish sentiment that is confounding Wall Street.

After double topping between August and October this year, the Nasdaq Biotech Index (IBB) smashed through its support level and fell roughly 10% through December, as you can see in the chart below.


But over the last five days the IBB has started to recover, and I expect this five-day uptrend to mark the start of a significant surge. Most notably in small-cap biotechs.

You see, for many small biotech plays, it’s execution and success, not overall market trends, that make big gains for us.

Things are setting up for big success among our biotech plays in 2019.

Here is everything you need to know.

Tiny “Power Plants” Living Inside You

There’s a new company out there that’s creating therapies based on the tiny “power plants” present in each and every cell in your body: mitochondria.

Mitochondria are complex organelles — like tiny organs inside your cells. We hear all about nuclear DNA, but these tiny power plants also come complete with their own set of biological blueprints.

As we get older, our mitochondria do too… and many age-related diseases could one day be treated using mitochondrial-based therapies (MBTs). Especially if they are diseases related to metabolism like obesity and diabetes.

And that’s exactly why one small biotech has caught my eye.

Fundamental discoveries about mitochondrial biology led to the founding of this company and I think it may turn out to be one of the biggest biotech opportunities of the year.

The Market for MBTs Is Huge

Age-related diseases, from Alzheimer’s to heart disease, are among the biggest markets in health care, if not the biggest.

For example, Forbes earlier this year reported the annual cost of care for Alzheimer’s patients eclipsed $277 billion in 2018.

Heart diseases is equally costly. The Centers for Disease Control (CDC) estimates heart disease costs the U.S. roughly $200 billion annually and is responsible for one out of every four deaths here in the U.S. alone.

There’s clearly a need for better drugs. And in this need lies our opportunity.

The company’s longevity and mitochondrial work are putting it in position to eventually be able to address some of the biggest health care problems in ways modern medicine never conceived previously.

For you this means the potential to make incredible gains in the near future.

For the full report on this company, including how you can get in on the ground floor for the biggest possible gains click here now.

Ray’s Cannabis Corner

Looking for new opportunities in pot for 2019?

One of your better bets to kick off the new year looks to be in New Mexico. Marijuana Business Daily is reporting:

2019 is shaping up to be a good year for New Mexico’s medical marijuana market, with action favorable to the industry expected from judges, legislators and a newly elected pro-cannabis governor.

More on how to tap this opportunity in coming issues.

For Technology Profits Daily,

Ray Blanco
Chief Technology Expert, Technology Profits Daily

Editor’s note: This is my biggest bombshell yet… “Alzheimer’s Disease Is Completely Treatable.”

One West Coast startup has discovered the key to eradicating Alzheimer’s and many other costly diseases.

Click here to get the details before the stock of this tiny neuro-tech lab goes through the roof…

You May Also Be Interested In:

The One Thing That Could Derail the Bull Market

The Archegos blowup was well contained – it didn’t create a contagion. But there’s a closely related risk that’s currently looming. It may be the only thing that could derail the current bull market…

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco